Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenanthridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 1/20 | 0.49 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 3/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.95 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenanthridine SCHEMBL31326572 | 0.98 | KDM4E (0.91) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL27479329 | 0.98 | GPR3 (0.91) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL30914262 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL8666 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL30823553 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL9106884 | 0.98 | GPR3 (1.00) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL23003530 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL2422346 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL460289 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 | |
| Phenanthridine SCHEMBL2421052 | 0.95 | GPR3 (0.95) | GPR3KDM4ECYP3A4TOP2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | claimed |
| EP-2686684-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | Enzo Life Sciences, Inc. (US) | 2014-01-22 | — | — | EP | claimed |
| WO-2012128898-A1 | MULTISIGNAL LABELING REAGENTS AND PROCESSES AND USES THEREFOR | ENZO LIFE SCIENCES, INC. (US) | 2012-09-27 | — | — | WO | claimed |
| CN-100376575-C | [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2008-03-26 | — | — | CN | claimed |
| CN-1955179-A | [1,4]diazepino[6,7,1-IJ]quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2007-05-02 | — | — | CN | claimed |
| CN-1662533-A | [1,4] diazepino [6,7, 1-IJ ] quinoline derivatives as antipsychotic and antiobesity agents | WYETH CORP (US) | 2005-08-31 | — | — | CN | claimed |
| US-20250367419-A1 | DRUG DELIVERY SYSTEM COMPRISING AN AGENT EFFECTIVE IN THE TREATMENT OR PREVENTION OF AN ESOPHAGEAL DISEASE FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2025-12-04 | — | — | US | disclosed |
| EP-4536665-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536195-A1 | DRUG DELIVERY SYSTEM COMPRISING AN AGENT EFFECTIVE IN THE TREATMENT OR PREVENTION OF AN ESOPHAGEAL DISEASE FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | EsoCap AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| CN-118370839-A | Surface charge inversion type amphiphilic platinum prodrug nano-particle and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023242098-A1 | NOVEL RAS INHIBITORS | KHR Biotec GmbH (DE) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023237431-A1 | DRUG DELIVERY SYSTEM COMPRISING AN AGENT EFFECTIVE IN THE TREATMENT OR PREVENTION OF AN ESOPHAGEAL DISEASE FOR THE APPLICATION TO ESOPHAGEAL MUCOUS MEMBRANES | ESOCAP AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | disclosed |
| WO-2002036607-A1 | PHENANTHRIDINE DERIVATIVES AND ANTITUMORAL MEDICAMENTS CONTAINING PHENANTHRIDINE | CLEMENT BERND (DE) | 2002-05-10 | — | — | WO | disclosed |
| CN-1238772-A | Novel phenanthridinium derivatives | NIPPON KAYAKU KK (JP) | 1999-12-15 | — | — | CN | disclosed |
| EP-0889886-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1999-01-13 | — | — | EP | disclosed |
| CN-1204321-A | Phenanthridine derivatives, process for preparing the same and drugs containing the same | BERND CLEMENT (DE) | 1999-01-06 | — | — | CN | disclosed |
| WO-1997035854-A1 | NOVEL PHENANTHRIDINES SUBSTITUTED IN THE 6 POSITION | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-10-02 | — | — | WO | disclosed |
| EP-0773933-A1 | OPTICALLY ACTIVE ISOMERS OF DIHYDREXIDINE AND ITS SUBSTITUTED ANALOGS | PURDUE RESEARCH FOUNDATION (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002513-A1 | OPTICALLY ACTIVE ISOMERS OF DIHYDREXIDINE AND ITS SUBSTITUTED ANALOGS | PURDUE RESEARCH FOUNDATION (US) | 1996-02-01 | — | — | WO | disclosed |